Unknown PHASE2 INTERVENTIONAL 2-arm NCT03971201

A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion

Sponsor: Anhui Provincial Hospital

Interventions Sorafenib hepatic resection

Updated 7 times since 2019 Last updated: Apr 8, 2021 Started: Sep 6, 2019 Primary completion: Dec 31, 2022 Completion: Jun 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03971201, this PHASE2 trial focuses on Hepatocellular Cancer and remains ongoing. Sponsored by Anhui Provincial Hospital, it has been updated 7 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Aug 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
May 2021 — Aug 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2021 — May 2021 [monthly]

Not Yet Recruiting PHASE2

▶ Show 2 earlier versions

Sep 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2
Jul 2019 — Sep 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anhui Provincial Hospital
Cancer Hospital of Guangxi Medical University
Eastern Hepatobiliary Surgery Hospital
Fujian Cancer Hospital
Sun Yat-sen University
Wenzhou People's Hospital
West China Hospital
White Plains Hospital

Data source: White Plains Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China